EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, ALXO:

15 Oct 25 08:00
LAST:

1.708

CHANGE:
 0.01		OPEN:
1.720		HIGH:
1.720		ASK:
0.000		VOLUME:
1.6K
CHG(%):
0.47		PREV:
1.700		LOW:
1.700		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
15 Oct 251.7201.7201.7001.7081.6K
14 Oct 251.7801.7901.6551.700525.6K
13 Oct 251.7001.9001.5501.850750.9K
10 Oct 251.9401.9401.6101.640835.7K
09 Oct 252.0102.0101.8801.940385K
08 Oct 251.8302.0601.8301.970488.8K
07 Oct 252.1202.1401.8101.830772.4K
06 Oct 252.2202.2702.1002.110494.6K
03 Oct 251.9052.2401.9052.1801.07M
02 Oct 251.8001.9101.7501.910888.9K

COMPANY PROFILE

Name:
About:ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Symposium; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:323 Allerton Avenue, South San Francisco, CA, United States, 94080
Website:https://www.alxoncology.com
CUSIP:00166B105
CIK:0001810182
ISIN:US00166B1052
FIGI:BBG00VR8SDG8

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:1.773.5%
MA10:1.8810.3%
MA20:1.710.3%
MA50:1.2734.9%
MA100:0.8993.0%
MA200:0.9187.7%
STO9:10.79 
STO14:10.79 
RSI14:47.79
WPR14:-87.41 
MTM14:-0.16
ROC14:-0.09 
ATR:0.21 
Week High:2.0620.6%
Week Low:1.5510.2%
Month High:2.2732.9%
Month Low:1.0287.7%
Year High:2.2732.9%
Year Low:0.40322.8%
Volatility:31.77